CO5611125A2 - Derivados de azetidina como antagonistas del receptor ccr-3 - Google Patents

Derivados de azetidina como antagonistas del receptor ccr-3

Info

Publication number
CO5611125A2
CO5611125A2 CO04091228A CO04091228A CO5611125A2 CO 5611125 A2 CO5611125 A2 CO 5611125A2 CO 04091228 A CO04091228 A CO 04091228A CO 04091228 A CO04091228 A CO 04091228A CO 5611125 A2 CO5611125 A2 CO 5611125A2
Authority
CO
Colombia
Prior art keywords
alkyl
denote
optionally substituted
phenyl
heterocyclic group
Prior art date
Application number
CO04091228A
Other languages
English (en)
Inventor
Grand Darren Mark Le
Clive Mccarthy
Clive Victor Walker
John James Woods
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206218A external-priority patent/GB0206218D0/en
Priority claimed from GB0229627A external-priority patent/GB0229627D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5611125A2 publication Critical patent/CO5611125A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

1.- Un compuesto según la Fórmula Ien forma de sal o libre, dondeAr es un fenilo opcionalmente substituido por uno o más substitutos seleccionados a partir de halógeno, C1-C8-alquilo, ciano o nitro;R1 es hidrógeno, o C1-C8-alquilo, opcionalmente substituido por hidroxi, C1-C8-alquilo, aciloxi, halógeno, carboxi, C1-C8-alcoxicarbonilo, -N(R4)R5, -CON(R6)R7 o por un grupo orgánico cíclico monovalente que tiene de 3 a 15 átomos en el sistema de anillo;R2 es hidrógeno, C1-C8-alquilo, o C3-C10-cicloalquilo, y R3 es C1-C8-alquilo substituido por fenilo, fenoxi, aciloxi o naftilo, o R3 es C3-C10-cicloalquilo que tiene opcionalmente un grupo benzo fusionado al mismo, un grupo heterocíclico que tiene 5 a 11 átomos de anillo de los cuales 1 a 4 son heteroátomos, fenilo o naftilo, substituyéndose opcionalmente dichos grupos fenilo, fenoxi o naftilo por uno o más substitutos seleccionados a partir de halógeno, ciano, hidroxi, acilo, nitro, -SO2NH2, C1-C8-alquilo opcionalmente substituido por C1-C8-alcoxi, C1-C8-haloalquilo, C1-C8-alcoxi, C1-C8-haloalcoxi, C1-C8-alquiltio, -SO2C1-C8-alquilo, C1-C8-alcoxicarbonilo, C1-C8-acilamino opcionalmente substituidos en el átomo de nitrógeno por C1-C8-alquilo, C1-C8-alquilamino, aminocarbonilo, C1-C8-alquilamino-carbonilo, di(C1-C8-alquil)amino, di(C1-C8-alquil)aminocarbonilo, di(C1-C8-alquil)aminocarbonil-metoxi, o o R2 o R3 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico que tiene de 5 a 10 átomos de anillo de los cuales 1, 2 o 3 son heteroátomos;R4 y R5 son cada uno independientemente hidrógeno o C1-C8-alquilo, o R4 es hidrógeno y R5 es hidroxi-C1-C8-alquilo, acilo, -SO2R8 o -CON(R6)R7, o R4 y R5 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico integrado por 5 o 6 miembros;R6 y R7 son cada uno independientemente hidrógeno o C1-C8-alquilo, o R6 y R7 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico integrado por 5 o 6 miembros;R8 es C1-C8-alquilo, C1-C8-haloalquilo, o fenilo opcionalmente substituido por C1-C8-alquilo;X es -C(=O)-, -O-, -CH2-, o CH(OH);Y es oxígeno o azufre;m es 1, 2, 3 o 4; y n, p y q son cada uno 0 o 1, n+p+q=1 o 2, n+q=1, p+q=1, y cuando n es 0, p es 0.
CO04091228A 2002-03-15 2004-09-14 Derivados de azetidina como antagonistas del receptor ccr-3 CO5611125A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0206218A GB0206218D0 (en) 2002-03-15 2002-03-15 Organic compounds
GB0229627A GB0229627D0 (en) 2002-12-19 2002-12-19 Organic compounds

Publications (1)

Publication Number Publication Date
CO5611125A2 true CO5611125A2 (es) 2006-02-28

Family

ID=28043401

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04091228A CO5611125A2 (es) 2002-03-15 2004-09-14 Derivados de azetidina como antagonistas del receptor ccr-3

Country Status (18)

Country Link
US (1) US7288537B2 (es)
EP (1) EP1487435A1 (es)
JP (2) JP4332433B2 (es)
KR (1) KR100706270B1 (es)
CN (1) CN1638761A (es)
AR (1) AR041786A1 (es)
AU (1) AU2003227072B2 (es)
BR (1) BR0308419A (es)
CA (1) CA2479266A1 (es)
CO (1) CO5611125A2 (es)
IL (1) IL164016A0 (es)
MX (1) MXPA04009057A (es)
NO (1) NO20044373L (es)
NZ (1) NZ535082A (es)
PL (1) PL371055A1 (es)
RU (1) RU2314292C2 (es)
TW (2) TW200800167A (es)
WO (1) WO2003077907A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
EP1638939A2 (en) * 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20070043013A1 (en) * 2003-09-15 2007-02-22 Le Grand Darren M 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases
GB0402101D0 (en) 2004-01-30 2004-03-03 Novartis Ag Organic compounds
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
GB0417801D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
CA2584342C (en) * 2004-10-20 2013-04-30 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0720390D0 (en) * 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) * 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
MX371290B (es) 2011-01-07 2020-01-24 Novartis Ag Formulaciones inmunosupresoras.
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
WO2019147862A1 (en) 2018-01-26 2019-08-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
CN110498750B (zh) * 2019-09-02 2021-10-15 南通大学 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2093456B (en) 1980-10-08 1984-12-05 Robins Co Inc A H 1-r1-3-phenozyazetidines
US5095014A (en) * 1990-12-07 1992-03-10 A. H. Robins Company, Incorporated 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
GB0117387D0 (en) 2001-07-17 2001-09-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20040091690A (ko) 2004-10-28
US20050222118A1 (en) 2005-10-06
AU2003227072A1 (en) 2003-09-29
JP2009102325A (ja) 2009-05-14
IL164016A0 (en) 2005-12-18
KR100706270B1 (ko) 2007-04-11
EP1487435A1 (en) 2004-12-22
MXPA04009057A (es) 2005-01-25
JP4332433B2 (ja) 2009-09-16
CA2479266A1 (en) 2003-09-25
RU2314292C2 (ru) 2008-01-10
NO20044373L (no) 2004-10-14
NZ535082A (en) 2006-08-31
AU2003227072B2 (en) 2006-08-10
JP2005526773A (ja) 2005-09-08
CN1638761A (zh) 2005-07-13
WO2003077907A1 (en) 2003-09-25
TW200305395A (en) 2003-11-01
TW200800167A (en) 2008-01-01
BR0308419A (pt) 2005-01-18
AR041786A1 (es) 2005-06-01
PL371055A1 (en) 2005-06-13
RU2004130487A (ru) 2005-07-10
US7288537B2 (en) 2007-10-30

Similar Documents

Publication Publication Date Title
CO5611125A2 (es) Derivados de azetidina como antagonistas del receptor ccr-3
ES2189502T3 (es) Metodo para la prevencion de citalopram.
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
ES2546851T3 (es) Inhibidores de fosfatidilinositol 3-cinasa
CO5080780A1 (es) Derivado de amida y antagonista de nociceptina
PE20030809A1 (es) Derivados de piperidina como antagonistas de la hormona concentradora de la melanina (mch)
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
CO6190521A2 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
CO5601018A2 (es) Derivados de n-fenil-2-pirimidin-amina
BRPI0506927A (pt) compostos orgánicos
ECSP055883A (es) Nuevos derivados de piridazin-3(2h)-ona
ECSP034611A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina
AR028531A1 (es) Compuestos organicos
CO5180568A1 (es) Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
CO6700838A2 (es) Compuestos sustituidos de banzamida
CO5080782A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
DOP2011000281A (es) Derivados de benzofurano
ES2260933T3 (es) Derivados del acido de tiazolina.
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
CO5590924A2 (es) Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6
CO4650117A1 (es) Derivados de bencilsulfuro y proceso para su produccion .

Legal Events

Date Code Title Description
FC Application refused